Could a modified MDMA ease autism symptoms? small trial begins

NCT ID NCT07303907

Recruiting now Symptom relief Sponsor: Definium Therapeutics US, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called DT402 (a form of MDMA) in 20 adults with autism spectrum disorder. The goal is to see if it can reduce the severity of social and communication problems. Participants will take the drug and report their experiences using simple rating scales. It is an early, open-label trial, meaning everyone knows they are getting the drug, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DT402 (R-MDMA, a form of MDMA)
What this could lead to: If it works, this could point toward a new treatment to help adults with autism feel less severe social and communication difficulties.
What could go wrong: This is a very small, early-phase trial with only 20 people and no placebo group, so results may not be reliable or apply to everyone. The drug is psychoactive and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial septal defect autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASD AUTISM SPECTRUM DISORDER

Contacts and locations

Locations

Spectrum Neuroscience and Treatment Institute
RECRUITING

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.